Avidity Biosciences (RNA) Enterprise Value: 2019-2025
Historic Enterprise Value for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to $3.7 billion.
- Avidity Biosciences' Enterprise Value rose 7.96% to $3.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$335.0 million, marking a year-over-year decrease of 151.99%. This contributed to the annual value of $2.0 billion for FY2024, which is 2514.77% up from last year.
- Per Avidity Biosciences' latest filing, its Enterprise Value stood at $3.7 billion for Q3 2025, which was up 66.49% from $2.2 billion recorded in Q2 2025.
- In the past 5 years, Avidity Biosciences' Enterprise Value ranged from a high of $3.7 billion in Q3 2025 and a low of -$69.8 million during Q3 2023.
- For the 3-year period, Avidity Biosciences' Enterprise Value averaged around $1.6 billion, with its median value being $2.0 billion (2024).
- In the last 5 years, Avidity Biosciences' Enterprise Value crashed by 115.67% in 2023 and then spiked by 5,045.78% in 2024.
- Over the past 5 years, Avidity Biosciences' Enterprise Value (Quarterly) stood at $709.2 million in 2021, then decreased by 15.71% to $597.8 million in 2022, then plummeted by 87.41% to $75.3 million in 2023, then skyrocketed by 2,514.77% to $2.0 billion in 2024, then rose by 7.96% to $3.7 billion in 2025.
- Its Enterprise Value stands at $3.7 billion for Q3 2025, versus $2.2 billion for Q2 2025 and $2.2 billion for Q1 2025.